These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 9607859

  • 1. Human immunodeficiency virus proviral DNA from peripheral blood and lymph nodes demonstrates concordant resistance mutations to zidovudine (codon 215) and didanosine (codon 74). Division of AIDS Treatment Research Initiative 003 Study Group.
    Mayers D, Bethel J, Wainberg MA, Weislow O, Schnittman S.
    J Infect Dis; 1998 Jun; 177(6):1730-3. PubMed ID: 9607859
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children.
    Principi N, Marchisio P, Esposito S, Rossi P, Gattinara GC, Galli L, Gabiano C, Zuccotti GV, Orlandi P.
    AIDS Res Hum Retroviruses; 1998 Dec 20; 14(18):1653-9. PubMed ID: 9870319
    [Abstract] [Full Text] [Related]

  • 5. Evidence for late stage compartmentalization of HIV-1 resistance mutations between lymph node and peripheral blood mononuclear cells.
    Haddad DN, Birch C, Middleton T, Dwyer DE, Cunningham AL, Saksena NK.
    AIDS; 2000 Oct 20; 14(15):2273-81. PubMed ID: 11089615
    [Abstract] [Full Text] [Related]

  • 6. Phenotypic resistance pattern of HIV-1 isolates with zidovudine and/or multidrug resistance mutations after didanosine-stavudine combination therapy.
    Pellegrin I, Segondy M, Garrigue I, Izopet J, Montes B, Pellegrin JL, Reynes J, Massip P, Puel J, Fleury H.
    J Acquir Immune Defic Syndr; 2000 Dec 15; 25(5):465-6. PubMed ID: 11141248
    [No Abstract] [Full Text] [Related]

  • 7. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
    Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N.
    AIDS; 1997 Jun 15; 11(7):895-901. PubMed ID: 9189215
    [Abstract] [Full Text] [Related]

  • 8. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee.
    Brun-Vézinet F, Boucher C, Loveday C, Descamps D, Fauveau V, Izopet J, Jeffries D, Kaye S, Krzyanowski C, Nunn A, Schuurman R, Seigneurin JM, Tamalet C, Tedder R, Weber J, Weverling GJ.
    Lancet; 1997 Oct 04; 350(9083):983-90. PubMed ID: 9329513
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
    Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS.
    AIDS; 2001 Jul 06; 15(10):1269-74. PubMed ID: 11426071
    [Abstract] [Full Text] [Related]

  • 13. Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy.
    Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, Merigan TC.
    Ann Intern Med; 1994 Aug 15; 121(4):263-8. PubMed ID: 7518658
    [Abstract] [Full Text] [Related]

  • 14. Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team.
    Shafer RW, Iversen AK, Winters MA, Aguiniga E, Katzenstein DA, Merigan TC.
    J Infect Dis; 1995 Jul 15; 172(1):70-8. PubMed ID: 7541064
    [Abstract] [Full Text] [Related]

  • 15. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
    Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb 01; 14(2):136-44. PubMed ID: 9052722
    [Abstract] [Full Text] [Related]

  • 16. Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
    Picard V, Angelini E, Maillard A, Race E, Clavel F, Chêne G, Ferchal F, Molina JM.
    J Infect Dis; 2001 Sep 15; 184(6):781-4. PubMed ID: 11517441
    [Abstract] [Full Text] [Related]

  • 17. HIV-1 syncytium-inducing phenotype, virus burden, codon 215 reverse transcriptase mutation and CD4 cell decline in zidovudine-treated patients.
    Kozal MJ, Shafer RW, Winters MA, Katzenstein DA, Aguiniga E, Halpern J, Merigan TC.
    J Acquir Immune Defic Syndr (1988); 1994 Aug 15; 7(8):832-8. PubMed ID: 7517448
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun 15; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 19. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy.
    Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H.
    J Infect Dis; 1998 Jun 15; 177(6):1506-13. PubMed ID: 9607827
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.